Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D F Hoth

Showing results (11-20 of 44) with videos related to

Pageof 5
Sort By:
Hospital Practice (Office Ed.)|September 25, 1992
Current status of HIV therapy: I. Antiretroviral agentsD F Hoth, M W Myers, D S Stein
Cancer Treatment Reports|February 1, 1985
Hypersensitivity reactions to amsacrineD J Perry, R B Weiss, D F Hoth
Seminars in Oncology|June 1, 1986
Clinical development of biological response modifiers: comparison with cytotoxic drugsM J Hawkins, D F Hoth, R E Wittes
Annals of Internal Medicine|October 15, 1994
NIH conference. HIV vaccine development: a progress reportD F Hoth, D P Bolognesi, L Corey, et al.
Cancer Research|August 1, 1987
Role of thymidine in biochemical modulation: a reviewP J O'Dwyer, S A King, D F Hoth, et al.
Journal of Acquired Immune Deficiency Syndromes|May 1, 1993
HIV vaccine trials: some design issues including sample size calculationD O Dixon, W N Rida, P E Fast, et al.
Statistics in Medicine|March 1, 1993
The use of external monitoring committees in clinical trials of the National Institute of Allergy and Infectious DiseasesS S Ellenberg, M W Myers, W C Blackwelder, et al.
NCI Monographs : a Publication of the National Cancer Institute|January 1, 1987
Methodology for the rational development of methotrexate analogs in the clinicB Leyland-Jones, P J O'Dwyer, D F Hoth, et al.
Investigational New Drugs|January 1, 1987
5-MethyltetrahydrohomofolateP J O'Dwyer, B H Wagner, D F Hoth, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1988
N-methylformamide: cytotoxic, radiosensitizer, or chemosensitizerK Clagett-Carr, G Sarosy, J Plowman, et al.
Pageof 5

Showing results (11-20 of 44) with videos related to

Sort By:
Pageof 5
Hospital Practice (Office Ed.)|September 25, 1992
Current status of HIV therapy: I. Antiretroviral agentsD F Hoth, M W Myers, D S Stein
Cancer Treatment Reports|February 1, 1985
Hypersensitivity reactions to amsacrineD J Perry, R B Weiss, D F Hoth
Seminars in Oncology|June 1, 1986
Clinical development of biological response modifiers: comparison with cytotoxic drugsM J Hawkins, D F Hoth, R E Wittes
Annals of Internal Medicine|October 15, 1994
NIH conference. HIV vaccine development: a progress reportD F Hoth, D P Bolognesi, L Corey, et al.
Cancer Research|August 1, 1987
Role of thymidine in biochemical modulation: a reviewP J O'Dwyer, S A King, D F Hoth, et al.
Journal of Acquired Immune Deficiency Syndromes|May 1, 1993
HIV vaccine trials: some design issues including sample size calculationD O Dixon, W N Rida, P E Fast, et al.
Statistics in Medicine|March 1, 1993
The use of external monitoring committees in clinical trials of the National Institute of Allergy and Infectious DiseasesS S Ellenberg, M W Myers, W C Blackwelder, et al.
NCI Monographs : a Publication of the National Cancer Institute|January 1, 1987
Methodology for the rational development of methotrexate analogs in the clinicB Leyland-Jones, P J O'Dwyer, D F Hoth, et al.
Investigational New Drugs|January 1, 1987
5-MethyltetrahydrohomofolateP J O'Dwyer, B H Wagner, D F Hoth, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1988
N-methylformamide: cytotoxic, radiosensitizer, or chemosensitizerK Clagett-Carr, G Sarosy, J Plowman, et al.
Pageof 5